Prostate And Other Male Cancers

FDA Issues Complete Response Letter to sBLA for Xgeva

Amgen announced that it received a complete response letter from the FDA for it supplemental Biologics License Application (sBLA) for Xgeva (denosumab) injection for the treatment of men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

USPSTF Guidelines Haven’t Changed PSA Screening Practice

Despite the 2008 changes in US Preventive Services Task Force (USPSTF) recommendations against prostate-specific antigen (PSA)-based screening for prostate cancer in men >75 years, screening rates remained unchanged for men of all ages between 2005-2010.